12/24/2009

Sanofi Pasteur secured FDA approval to promote a high-dose formulation of its Fluzone seasonal flu vaccine for people 65 and older. Sanofi's application was supported by clinical data showing the superiority of high-dose Fluzone over its original formulation in eliciting an immune response.

Full Story:
Reuters

Related Summaries